Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
October, 2026
October 2026
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Chokri Ben Lamine: Pacritinib Is a Key JAK Inhibitor for Cytopenic Myelofibrosis
AI generated
May 23, 2026, 16:43

Chokri Ben Lamine: Pacritinib Is a Key JAK Inhibitor for Cytopenic Myelofibrosis

Chokri Ben Lamine, Assistant Consultant at King Faisal Specialist Hospital and Research Center, shared a post on X:

“Pacritinib (Vonjo): A Key JAK Inhibitor for Cytopenic Myelofibrosis

Credits for sharing: Dr. Omar Albanyan

Pacritinib is uniquely developed for patients with Myelofibrosis and severe thrombocytopenia and/or anemia.

Why Pacritinib Is Different

Key Targets

  • JAK2
  • IRAK1
  • ACVR1
  • Minimal JAK1 inhibition (JAK1-sparing)

JAK1-sparing may help reduce myelosuppression while preserving immune signaling.

Benefits in Thrombocytopenic MF

Approved for symptomatic myelofibrosis with platelet counts less than 50 ×10⁹/L

  • Effective spleen volume reduction
  • Improvement in constitutional symptoms
  • No dose reduction required in severe thrombocytopenia

Benefits in Anemic MF

ACVR1 inhibition may:

  • Reduce hepcidin levels
  • Increase iron availability
  • Improve erythropoiesis
  • Enhance transfusion independence

In vitro data suggest stronger ACVR1 inhibition compared with Momelotinib, although this does not confirm superior clinical efficacy.

Key Clinical Trials

  • PERSIST-2
    Demonstrated significant spleen and symptom responses in thrombocytopenic MF.
  • PACIFICA
    Confirmed efficacy and manageable safety in patients with platelet counts <50 ×10⁹/L.

Ideal Patient Profile

  • Platelet less than 50 ×10⁹/L
  • Concurrent anemia or transfusion dependence
  • Massive splenomegaly
  • Significant constitutional symptoms
  • Unsuitability for Ruxolitinib or Fedratinib because of thrombocytopenia

Common Adverse Events

  • Diarrhea (most common; usually early and manageable)
  • Nausea
  • Anemia
  • Thrombocytopenia
  • Peripheral edema

Clinical Pearl

Pacritinib is often considered the preferred JAK inhibitor when severe thrombocytopenia and anemia coexist.

MCQ

Which feature most distinguishes Pacritinib from other JAK inhibitors?

  1. Intravenous administration
  2. Potent JAK1 inhibition
  3. Use in platelet counts <50 ×10⁹/L
  4. Causes profound myelosuppression

Answer: C. Use in platelet counts <50 ×10⁹/L

Key References

  • NCCN Guidelines for Myeloproliferative Neoplasms
  • Pacritinib (Vonjo) Prescribing Information
  • PERSIST-2 Trial Publication
  • PACIFICA Trial Update”

Chokri Ben Lamine

Other posts featuring Chokri Ben Lamine on Hemostasis Today.

anemia Blood cancer Chokri Ben Lamine Cytopenic Myelofibrosis Diarrhea Fedratinib Health Hematology Hemostasis News Hemostasis Today JAK Inhibitor Medicine Momelotinib Nausea Omar Albanyan PACIFICA Pacritinib Peripheral edema PERSIST-2 Platelet ruxolitinib severe thrombocytopenia splenomegaly Thrombocytopenic MF
NewsFeed